Mitosis Is a Source of Potential Markers for Screening and Survival and Therapeutic Targets in Cervical Cancer

The effect of preventive human papillomavirus (HPV) vaccination on the reduction of the cervical cancer (CC) burden will not be known for 30 years. Therefore, it’s still necessary to improve the procedures for CC screening and treatment. The objective of this study was to identify and characterize cellular targets that could be considered potential markers for screening or therapeutic targets. A pyramidal strategy was used. Initially the expression of 8,638 genes was compared between 43 HPV16-positive CCs and 12 healthy cervical epitheliums using microarrays. A total of 997 genes were deregulated, and 21 genes that showed the greatest deregulation were validated using qRT-PCR. The 6 most upregulated genes (CCNB2, CDC20, PRC1, SYCP2, NUSAP1, CDKN3) belong to the mitosis pathway. They were further explored in 29 low-grade cervical intraepithelial neoplasias (CIN1) and 21 high-grade CIN (CIN2/3) to investigate whether they could differentiate CC and CIN2/3 (CIN2+) from CIN1 and controls. CCNB2, PRC1, and SYCP2 were mostly associated with CC and CDC20, NUSAP1, and CDKN3 were also associated with CIN2/3. The sensitivity and specificity of CDKN3 and NUSAP1 to detect CIN2+ was approximately 90%. The proteins encoded by all 6 genes were shown upregulated in CC by immunohistochemistry. The association of these markers with survival was investigated in 42 CC patients followed up for at least 42 months. Only CDKN3 was associated with poor survival and it was independent from clinical stage (HR = 5.9, 95%CI = 1.4–23.8, p = 0.01). CDKN3 and NUSAP1 may be potential targets for the development of screening methods. Nevertheless, further studies with larger samples are needed to define the optimal sensitivity and specificity. Inhibition of mitosis is a well-known strategy to combat cancers. Therefore, CDKN3 may be not only a screening and survival marker but a potential therapeutic target in CC. However, whether it’s indispensable for tumor growth remains to be demonstrated.

[1]  B. Molnár,et al.  S1978 Reversal of Gene Expression Pattern Changes in the Colorectal Normal-Adenoma But Less in the Normal-Carcinoma Pathway By NS-398 Selective COX-2 Inhibitor , 2009 .

[2]  Joakim Dillner,et al.  Screening and cervical cancer cure: population based cohort study , 2012, BMJ : British Medical Journal.

[3]  J. Cuzick.  Long-term cervical cancer prevention strategies across the globe. , 2010, Gynecologic oncology.

[4]  M. Lehtinen,et al.  Aspects of Prophylactic Vaccination against Cervical Cancer and Other Human Papillomavirus-Related Cancers in Developing Countries , 2011, Infectious diseases in obstetrics and gynecology.

[5]  C. Wheeler,et al.  A Pooled Analysis of Continued Prophylactic Efficacy of Quadrivalent Human Papillomavirus (Types 6/11/16/18) Vaccine against High-grade Cervical and External Genital Lesions , 2009, Cancer Prevention Research.

[6]  Christopher P. Arthur,et al.  Insights into Antiparallel Microtubule Crosslinking by PRC1, a Conserved Nonmotor Microtubule Binding Protein , 2010, Cell.

[7]  Jan Hellemans,et al.  Accurate and objective copy number profiling using real-time quantitative PCR. , 2010, Methods.

[8]  David Yang,et al.  Identification of cervical cancer markers by cDNA and tissue microarrays. , 2003, Cancer research.

[9]  R. Tibshirani,et al.  Significance analysis of microarrays applied to the ionizing radiation response , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[10]  L. Orozco,et al.  Amplified Genes May Be Overexpressed, Unchanged, or Downregulated in Cervical Cancer Cell Lines , 2012, PloS one.

[11]  H. Bartsch,et al.  International Agency for Research on Cancer. , 1969, WHO chronicle.

[12]  A. Worster,et al.  Understanding receiver operating characteristic (ROC) curves. , 2006, CJEM.

[13]  T. Wright.  Cervical Cancer Screening in the 21st Century: Is it Time to Retire the PAP Smear? , 2007, Clinical obstetrics and gynecology.

[14]  Marrije R Buist,et al.  Gene expression in early stage cervical cancer. , 2008, Gynecologic oncology.

[15]  P. Martin-Hirsch,et al.  p16(INK4a) immunostaining in cytological and histological specimens from the uterine cervix: a systematic review and meta-analysis. , 2009, Cancer treatment reviews.

[16]  Kenneth R. Shroyer,et al.  Biomarkers of Cervical Dysplasia and Carcinoma , 2011, Journal of oncology.

[17]  A. Östör,et al.  Natural history of cervical intraepithelial neoplasia: a critical review. , 1993, International Journal of Gynecological Pathology.

[18]  Liang Liang,et al.  Dynamic changes in gene expression in vivo predict prognosis of tamoxifen-treated patients with breast cancer , 2010, Breast Cancer Research.

[19]  Brad T. Sherman,et al.  Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists , 2008, Nucleic acids research.

[20]  C. Wheeler,et al.  Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. , 2012, The Lancet. Oncology.

[21]  Meihong Lin,et al.  Identification of PRC1 as the p53 target gene uncovers a novel function of p53 in the regulation of cytokinesis , 2004, Oncogene.

[22]  K. Hui,et al.  Upregulation of Rac GTPase-Activating Protein 1 Is Significantly Associated with the Early Recurrence of Human Hepatocellular Carcinoma , 2011, Clinical Cancer Research.

[23]  Eytan Domany,et al.  Identification of a proliferation gene cluster associated with HPV E6/E7 expression level and viral DNA load in invasive cervical carcinoma , 2005, Oncogene.

[24]  K. Shokat,et al.  Targeting the cancer kinome through polypharmacology , 2010, Nature Reviews Cancer.

[25]  K. Nakayama,et al.  Ubiquitin ligases: cell-cycle control and cancer , 2006, Nature Reviews Cancer.

[26]  H. Yoshikawa,et al.  Detection and Typing of Multiple Genital Human Papillomaviruses by DNA Amplification with Consensus Primers , 1991, Japanese journal of cancer research : Gann.

[27]  Steven Wolinsky,et al.  The use of polymerase chain reaction amplification for the detection of genital human papillomaviruses , 1989 .

[28]  R. Medema,et al.  Shared and separate functions of polo-like kinases and aurora kinases in cancer , 2010, Nature Reviews Cancer.

[29]  B. Romanowski.  Long term protection against cervical infection with the human papillomavirus: Review of currently available vaccines , 2011, Human vaccines.

[30]  C. Meijer,et al.  Rapid detection of human papillomavirus in cervical scrapes by combined general primer-mediated and type-specific polymerase chain reaction , 1990, Journal of clinical microbiology.

[31]  Viji M. Draviam,et al.  The Localization of Human Cyclins B1 and B2 Determines Cdk1 Substrate Specificity and Neither Enzyme Requires Mek to Disassemble the Golgi Apparatus , 2001, The Journal of cell biology.

[32]  K. Basso,et al.  Gene dosage alterations revealed by cDNA microarray analysis in cervical cancer: Identification of candidate amplified and overexpressed genes , 2007, Genes, chromosomes & cancer.

[33]  Peter M Schlag,et al.  Identification of early molecular markers for breast cancer , 2011, Molecular Cancer.

[34]  C. Pelizzari,et al.  MUC1-associated proliferation signature predicts outcomes in lung adenocarcinoma patients , 2010, BMC Medical Genomics.

[35]  M. Pfaffl,et al.  A new mathematical model for relative quantification in real-time RT-PCR. , 2001, Nucleic acids research.

[36]  M. Stoler,et al.  Using Biomarkers as Objective Standards in the Diagnosis of Cervical Biopsies , 2010, The American journal of surgical pathology.

[37]  Abdul Ghaaliq Lalkhen,et al.  Clinical tests: sensitivity and specificity , 2008 .

[38]  R. Srinivasan,et al.  Functional biomarkers in cervical precancer: An overview , 2009, Diagnostic cytopathology.

[39]  Bin Nan,et al.  Gene expression analysis of preinvasive and invasive cervical squamous cell carcinomas identifies HOXC10 as a key mediator of invasion. , 2007, Cancer research.

[40]  R. Saxena,et al.  ErbB family receptor inhibitors as therapeutic agents in breast cancer: Current status and future clinical perspective , 2012, Medicinal research reviews.

[41]  D. Millar,et al.  Comparison of a novel HPV test with the Hybrid Capture II (hcII) and a reference PCR method shows high specificity and positive predictive value for 13 high-risk human papillomavirus infections. , 2008, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[42]  R. Ferris,et al.  Identification of differentially expressed genes in HPV-positive and HPV-negative oropharyngeal squamous cell carcinomas. , 2007, European journal of cancer.

[43]  C J L M Meijer,et al.  The causal relation between human papillomavirus and cervical cancer. , 2002, Journal of clinical pathology.

[44]  Viv Bewick,et al.  Statistics review 13: Receiver operating characteristic curves , 2004, Critical care.

[45]  J. Paramio,et al.  Molecular Signature of HPV-Induced Carcinogenesis: pRb, p53 and Gene Expression Profiling , 2009, Current genomics.

[46]  V. Hasselblad,et al.  Evaluation of cervical cytology. , 1999, Evidence report/technology assessment.

[47]  S. Hardy,et al.  Inside the human cancer tyrosine phosphatome , 2010, Nature Reviews Cancer.

[48]  L. Trusolino,et al.  Oncogene addiction as a foundational rationale for targeted anti-cancer therapy: promises and perils , 2011, EMBO molecular medicine.

[49]  Rodrigo Lopez,et al.  A new bioinformatics analysis tools framework at EMBL–EBI , 2010, Nucleic Acids Res..

[50]  Roger Brent,et al.  C dil, a Human Gl and S Phase Protein Phosphatase That Associates with Cdk2 , 2003 .

[51]  T. Hunter,et al.  PRC1 is a microtubule binding and bundling protein essential to maintain the mitotic spindle midzone , 2002, The Journal of cell biology.

[52]  C. Mathers,et al.  Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 , 2010, International journal of cancer.

[53]  M. Mori,et al.  A New E6/P63 Pathway, Together with a Strong E7/E2F Mitotic Pathway, Modulates the Transcriptome in Cervical Cancer Cells , 2007, Journal of Virology.

[54]  G. Hannon,et al.  Chromosomal mapping of the genes for the human cell cycle proteins cyclin C (CCNC), cyclin E (CCNE), p21 (CDKN1) and KAP (CDKN3). , 1995, Cytogenetics and cell genetics.

[55]  H. Lawson,et al.  Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP). , 2007, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[56]  Ewelina Bolcun-Filas,et al.  Genetic Evidence That Synaptonemal Complex Axial Elements Govern Recombination Pathway Choice in Mice , 2011, Genetics.

[57]  M. Newton,et al.  Fundamental differences in cell cycle deregulation in human papillomavirus-positive and human papillomavirus-negative head/neck and cervical cancers. , 2007, Cancer research.

[58]  M. Mori,et al.  A Genomic Approach Reveals a Novel Mitotic Pathway in Papillomavirus Carcinogenesis , 2004, Cancer Research.

[59]  W. Kim,et al.  NF-Y–Dependent Cyclin B2 Expression in Colorectal Adenocarcinoma , 2007, Clinical Cancer Research.

[60]  Erich A. Nigg,et al.  KIF14 and citron kinase act together to promote efficient cytokinesis , 2006, The Journal of cell biology.

[61]  Jennifer S Lin,et al.  Liquid-Based Cytology and Human Papillomavirus Testing to Screen for Cervical Cancer: A Systematic Review for the U.S. Preventive Services Task Force , 2011, Annals of Internal Medicine.

[62]  N. Muñoz,et al.  Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. , 2010, The Lancet. Oncology.

[63]  B. Molnár,et al.  Reversal of gene expression changes in the colorectal normal-adenoma pathway by NS398 selective COX2 inhibitor , 2010, British Journal of Cancer.

[64]  S. Pecorelli.  Corrigendum to “Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium” , 2010 .

[65]  Hai-Meng Zhou,et al.  Use of Serum Circulating Ccnb2 in Cancer Surveillance , 2010, The International journal of biological markers.

[66]  S. Wacholder,et al.  Human papillomavirus testing in the prevention of cervical cancer. , 2011, Journal of the National Cancer Institute.

[67]  Brad T. Sherman,et al.  Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources , 2008, Nature Protocols.

[68]  J. Walboomers,et al.  General primer‐mediated polymerase chain reaction permits the detection of sequenced and still unsequenced human papillomavirus genotypes in cervical scrapes and carcinomas , 1990, International journal of cancer.

[69]  Cary A Moody,et al.  Human papillomavirus oncoproteins: pathways to transformation , 2010, Nature Reviews Cancer.

[70]  M. von Knebel Doeberitz,et al.  Identification of high‐grade cervical dysplasia by the detection of p16INK4a in cell lysates obtained from cervical samples , 2006, Cancer.

[71]  J. Rader,et al.  Profiling microdissected epithelium and stroma to model genomic signatures for cervical carcinogenesis accommodating for covariates. , 2007, Cancer research.

[72]  Gur Pines,et al.  The ERBB network: at last, cancer therapy meets systems biology , 2012, Nature Reviews Cancer.

[73]  M. Mansukhani,et al.  Identification of copy number gain and overexpressed genes on chromosome arm 20q by an integrative genomic approach in cervical cancer: Potential role in progression , 2008, Genes, chromosomes & cancer.

[74]  K. Shroyer,et al.  Human papillomavirus testing and molecular markers of cervical dysplasia and carcinoma , 2007, Cancer.

[75]  A. Anttila,et al.  Age-specific evaluation of primary human papillomavirus screening vs conventional cytology in a randomized setting. , 2009, Journal of the National Cancer Institute.

[76]  D. Patel,et al.  Compromised Spindle Assembly Checkpoint due to Altered Expression of Ubch10 and Cdc20 in Human Papillomavirus Type 16 E6- and E7-Expressing Keratinocytes , 2010, Journal of Virology.

[77]  J. Ferrell,et al.  The Roles of Cyclin A2, B1, and B2 in Early and Late Mitotic Events , 2010, Molecular biology of the cell.

[78]  S. Franceschi,et al.  HPV prevalence and accuracy of HPV testing to detect high‐grade cervical intraepithelial neoplasia , 2012, International journal of cancer.